Acetylation genotype and phenotype in patients with systemic lupus erythematosus

Pharmacological Reports

Volumn 58, Issue 1, 2006, Pages 22-29

  Rychlik Sych, Mariola ^a   Skretkowicz, Jadwiga ^a   Gawrońska Szklarz, Barbara ^b   Górnik, Wanda ^b   Sysa Jedrzejowska, Anna ^a   Skretkowicz Szarmach, Kamila ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

N acetyltransferase 2; Polymorphism; Systemic lupus erythematosus

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG URINE LEVEL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; XENOBIOTIC METABOLISM;

EID: 33646202127     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Agundez JAG, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA et al.: Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics, 1996, 6, 501-512.
2. Blum M, Demierre A, Grant DM,Heirn M, Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA, 1991, 88, 5237-5241.
3. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I: Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res, 1996, 56, 3961-3966.
4. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Muller A, Roots I: Arylamine N-acetyltransferase activity in man. Drug Metab Rev, 1999, 31, 489-507.
5. Cascorbi I, Brockmöller J, Bauer S, Reurn T, Roots I: NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics, 1996, 6, 257-259.
6. Dańczak-Pazdrowska A, Prokop J: Significance of the immune cells in pathogenesis and therapy of lupus erythematosus. (Polish) Post Dermatol, 1999, 16, 231-243.
7. Deguchi T: Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem, 1992, 267, 18140-18147.
8. Delomenie CDM, Grant P, Mathelier-Fusade C: N-acetylation genotype and risk of severe reactions to sulfonamides in AIDS patients. Br J Clin Pharmacol, 1994, 38, 581-582.
9. Drozd M, Gierek T, Jendryczko A: N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma, 1987, 34, 481-484.
10. Eidus L, Varughese P, Hodgkin MM, Hsu AH, McRae KB: Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis. Bull World Health Organ, 1973, 49, 507-516.
11. Evans DA: N-acetyltransferase. Pharmacol Ther, 1989, 42, 157-234.
12. Fishbein E, Alarcon-Segovia D: Slow acetylation phenotype in systemic lupus erythematosus, Arthritis Rheum, 1979, 22, 95-96.
13. Gil JP, Lechner MC.: Increased frequency of wilde-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis, 1998, 19, 37-41.
14. Heim M, Meyer UA: Genotyping poor metabolisers of debrisoquine by allele specific PCR amplification. Lancet, 1990, 336, 529-532.
15. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I: Association of arylamine N-acetyltransferase NAT 1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics, 1999, 9, 103-111.
16. Hubbard AL, Harrison DJ, Moyes C Wyllie AH, Cunningham C, Mannion E, Smith CA: N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut, 1997, 41, 229-234.
17. Johansson EA, Mustakallio KK, Mattila MM, Tiilikainen A: Cutaneous reactions to drugs, acetylation phenotype, and HLA antigens in patients with and without systemic lupus erythematosus. Ann Clin Res, 1976, 8, 126-128.
18. Ladero JM, Agundez JA, Ofivera. M, Lazano L, Rodriguez-Lescure A, Diaz-Rubio M, Benitez J: N-acetyltransferase 2 single-nucleotide polymorphism and risk of gastric carcinoma. Eur Clin Pharmacol, 2002, 58, 115-118.
19. Larsson R, Karlsson E, Molin L: Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Med Scand, 1977, 201, 223-226.
20. Lee BL, Wong D, Benowitz NL, Sullam PM: Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther, 1993, 53, 529-535.
21. Lin HJ, Han Ch Y, Lin BY, Hardy S: Ethnic distribution of slow acetylator mutation in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics, 1994, 4, 125-134.
22. Milejski P, Orzechowska-Juzwenko K, Kamienowski J, Horoch E, Niewiński P, Hurkacz M, Rzemisławska Z: Clinical significance of polymorfism of sparteine oxidation and sulfadimidine acetylation in Parkinsons disease patients. (Polish) Neurol Neurochir Pol, 1999, 33, 1017-1026.
23. Milejski P, Orzechowska-Juzwenko K, Kamienowski J, Horoch E, Niewiński P, Hurkacz; M, Rzemisławska Z: Oxidation and acetylation polymorphism of drugs in epileptic patients. Eur J Clin Pharmacol, 1997, Suppl. 57, 76.
24. Milejski P, Orzechowska-Juzwenko K, Kamienowski J, Horoch E, Niewiński P, Hurkacz M, Rzemisławska Z: Significance of pharmacogenetics in safe pharmacotherapy of neurologic syndromes. Cases of root syndromes and multiple sclerosis. (Polish) Farmacja Polska, 1998, 54, 311-317.
25. Orłowska-Westwood B, Skretkowicz J, Orszulak D: Acetylation phenotype in systemic 1upus erythematosus patients. (Polish) Pol Arch Med Wewn, 1980, 64, 431-434.
26. Orzechowska-Juzwenko Y, Milejski P: Acetylation phenotype and its clinical significance. (Polish) Pol Tyg Lek, 1982, 37, 1365-1367.
27. Orzechowska-Juzwenko K, Wiela-Hojeńska, Milejski P, Cieślińska A, Hudziec P, Adamska M: Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drugs and xenobiotics by oxidation and acetylation in women with breast cancer. (Polish) Przegl Lek, 1997, 54, 103-106.
28. Reidenberg MM, Drayer DE, Lorenzo B, Strom BL, West SL, Snyder ES, Freundlich B et al.: Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic 1upus erythematosus. Arthritis Rheum, 1993, 36, 7, 971-973.
29. Reidenberg MM, Martin JH: Acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos, 1974, 2, 71-73.
30. Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Brdy F: NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics, 1997, 7, 131-135.
31. Samborski W, Zaba R: Pathogenesis of systemic lupus erythematosus. An uptade on clinical symptoms, diagnosis and treatment. (Polish) Post Dermatol Alergol, 2001, 1, 5-10.
32. Skretkowicz J: Pharmacogenetic Aspects of Therapy. Materials of Round-Table Conference. (Polish) Probl Ter Monit, 1994, 5, 36-41.
33. Sonnhag C, Karlsson E, Hed J: Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand 1979, 206, 245.
34. Spurr NV, Gough AC, Chinegwundoh FJ: Polymorphisms in Long-Metabolizing Enzymes as Modifiers of Cancer Risk. Clin Chem, 1995, 12, 1864-1869.
35. Stranberg I, Boman G, Hassler L: Acetylator phenotype in patients with hydralazine induced lupoid syndrome. Acta Med Scand, 1976, 200, 367.
36. Sysa-Jerzejowska. A: Diseases of connective tissue (Polish). In: Clinical Immunology ed M. Kowalski, Mediton, Lsódź, 2000, 341-347.
37. von Feldt JM: Systemic lupus erythematosus. (Polish) Postgraduate Medicine, 1996, 4, 6, 35-45.
38. von Schmiedeberg S, Fritsche E, Ronnau. AC, Specker C Golka K, Richter-Hintz D, Schuppe HC et al.: Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med. Biol, 1999, 45, 147-152.
39. Wiegan EB, Dennis S, Reele SB, Like DR: Reassessment of dapsone as a marker of acetylator phenotypes. Intern J Clin Pharmacol Ther Toxicol, 1991, 29, 262-268.
40. Wiela-Hojeńska A, Milejski P, Orzechowska-Juzwenko K, Usnarska-Zubkiewicz L, Urbaniak-Kujda D, Kotlarek-Haus S: Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms. (Polish) Przegi Lek, 1997, 54, 163-166.
41. Wolkenstein P, Carriere PV, Charue D, Bastuji-Garin S, Revuz J, Roujean X, Beaune P et al.: A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics, 1995, 5, 255-258.